Sean Michael Smith Neoleukin Therapeutics, Inc. (NLTX) insider trading activity

NLTX Quotes by TradingView

Sean Michael Smith is Interim CFO, Prin Acct Off of Neoleukin Therapeutics, Inc.. Currently has a direct ownership of 21,637 shares of NLTX, which is worth approximately $0. The most recent transaction as insider was on Aug 11, 2023, when has been sold 1,323 shares (Common Stock) at a price of $0.62 per share, resulting in proceeds of $820. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 21.6K
0% 3M change
0% 12M change
Total Value Held $0

Sean Michael Smith Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 11 2023
SELL
Open market or private sale
$820 $0.62 p/Share
1,323 Reduced 5.76%
21,637 Common Stock
Aug 10 2023
BUY
Exercise of conversion of derivative security
-
5,000 Added 17.88%
22,960 Common Stock
Feb 02 2023
SELL
Open market or private sale
$1,989 $0.6 p/Share
3,316 Reduced 17.2%
15,960 Common Stock
Feb 01 2023
BUY
Exercise of conversion of derivative security
-
12,500 Added 39.34%
19,276 Common Stock
Aug 10 2022
SELL
Open market or private sale
$1,638 $0.99 p/Share
1,655 Reduced 19.63%
6,776 Common Stock
Aug 10 2022
BUY
Exercise of conversion of derivative security
-
5,000 Added 37.23%
8,431 Common Stock
SMS

Sean Michael Smith

Interim CFO, Prin Acct Off
Seattle, WA

Track Institutional and Insider Activities on NLTX

Follow Neoleukin Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NLTX shares.

Notify only if

Insider Trading

Get notified when an Neoleukin Therapeutics, Inc. insider buys or sells NLTX shares.

Notify only if

News

Receive news related to Neoleukin Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on NLTX